{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T19:42:24Z","timestamp":1772134944145,"version":"3.50.1"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T00:00:00Z","timestamp":1745280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T00:00:00Z","timestamp":1745280000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Genes Immun"],"DOI":"10.1038\/s41435-025-00325-7","type":"journal-article","created":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T08:06:05Z","timestamp":1745309165000},"page":"179-189","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A scan of pleiotropic immune mediated disease genes identifies novel determinants of baseline FVIII inhibitor status in hemophilia A"],"prefix":"10.1038","volume":"26","author":[{"given":"Marcio A.","family":"Almeida","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent P.","family":"Diego","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin R.","family":"Viel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernadette W.","family":"Luu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karin","family":"Haack","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raja","family":"Rajalingam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Afshin","family":"Ameri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meera","family":"Chitlur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia","family":"Rydz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Lillicrap","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raymond G.","family":"Watts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig M.","family":"Kessler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Ramsey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Long V.","family":"Dinh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerry S.","family":"Powell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eron G.","family":"Manusov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan M.","family":"Peralta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruayda","family":"Bouls","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shirley M.","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Min","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos M.","family":"Murillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry","family":"Mead","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul V.","family":"Lehmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eli J.","family":"Fine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel A.","family":"Escobar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satish","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara A.","family":"Konkle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Williams-Blangero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carol K.","family":"Kasper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Almasy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shelley A.","family":"Cole","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6250-5723","authenticated-orcid":false,"given":"John","family":"Blangero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4550-278X","authenticated-orcid":false,"given":"Tom E.","family":"Howard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,22]]},"reference":[{"key":"325_CR1","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.blre.2013.06.002","volume":"27","author":"M Franchini","year":"2013","unstructured":"Franchini M, Mannucci PM. Hemophilia A in the third millennium. Blood Rev. 2013;27:179\u201384.","journal-title":"Blood Rev"},{"key":"325_CR2","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1517\/21678707.2016.1127157","volume":"4","author":"J Klintman","year":"2016","unstructured":"Klintman J, Berntorp E. Epidemiological aspects of inhibitor development in hemophilia and strategies of management. Expert Opin Orphan Drugs. 2016;4:153\u201368.","journal-title":"Expert Opin Orphan Drugs"},{"key":"325_CR3","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/ijlh.12659","volume":"39","author":"JD Lai","year":"2017","unstructured":"Lai JD, Lillicrap D. Factor VIII inhibitors: Advances in basic and translational science. Int J Lab Hematol. 2017;39:6\u201313.","journal-title":"Int J Lab Hematol"},{"key":"325_CR4","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/bjh.16377","volume":"189","author":"M Cormier","year":"2020","unstructured":"Cormier M, Batty P, Tarrant J, Lillicrap D. Advances in knowledge of inhibitor formation in severe haemophilia A. Br J Haematol. 2020;189:39\u201353.","journal-title":"Br J Haematol"},{"key":"325_CR5","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1038\/nrg1617","volume":"6","author":"J Graw","year":"2005","unstructured":"Graw J, Brackmann HH, Oldenburg J, Schneppenheim R, Spannagl M, Schwaab R. Haemophilia A: from mutation analysis to new therapies. Nat Rev Genet. 2005;6:488\u2013501.","journal-title":"Nat Rev Genet"},{"key":"325_CR6","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/j.1365-2516.2006.01361.x","volume":"12","author":"J Oldenburg","year":"2006","unstructured":"Oldenburg J, Pavlova A. Genetic risk factors for inhibitors to factors VIII and IX. Haemophilia. 2006;12:15\u201322.","journal-title":"Haemophilia"},{"key":"325_CR7","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1182\/blood-2008-02-124941","volume":"112","author":"S Lacroix-Desmazes","year":"2008","unstructured":"Lacroix-Desmazes S, Navarrete AM, Andre S, Bayry J, Kaveri SV, Dasgupta S. Dynamics of factor VIII interactions determine its immunologic fate in hemophilia A. Blood. 2008;112:240\u20139.","journal-title":"Blood"},{"key":"325_CR8","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1111\/j.1365-2516.2011.02517.x","volume":"17","author":"TE Howard","year":"2011","unstructured":"Howard TE, Yanover C, Mahlangu J, Krause A, Viel KR, Kasper CK, et al. Haemophilia management: time to get personal? Haemophilia. 2011;17:721\u20138.","journal-title":"Haemophilia"},{"key":"325_CR9","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1182\/asheducation-2014.1.372","volume":"2014","author":"BM Reipert","year":"2014","unstructured":"Reipert BM. Risky business of inhibitors: HLA haplotypes, gene polymorphisms, and immune responses. Hematol Am Soc Hematol Educ Program. 2014;2014:372\u20138.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"325_CR10","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/ejh.12495","volume":"94","author":"E Bardi","year":"2015","unstructured":"Bardi E, Astermark J. Genetic risk factors for inhibitors in haemophilia A. Eur J Haematol. 2015;94:7\u201310.","journal-title":"Eur J Haematol"},{"key":"325_CR11","doi-asserted-by":"publisher","first-page":"2922","DOI":"10.1182\/blood-2011-09-379453","volume":"119","author":"SC Gouw","year":"2012","unstructured":"Gouw SC, van den Berg HM, Oldenburg J, Astermark J, de Groot PG, Margaglione M, et al. F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis. Blood. 2012;119:2922\u201334.","journal-title":"Blood"},{"key":"325_CR12","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1111\/j.1365-2516.2011.02700.x","volume":"18","author":"CH Miller","year":"2012","unstructured":"Miller CH, Benson J, Ellingsen D, Driggers J, Payne A, Kelly FM, et al. F8 and F9 mutations in US haemophilia patients: correlation with history of inhibitor and race\/ethnicity. Haemophilia. 2012;18:375\u201382.","journal-title":"Haemophilia"},{"key":"325_CR13","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1182\/blood-2013-02-483263","volume":"122","author":"CL Eckhardt","year":"2013","unstructured":"Eckhardt CL, van Velzen AS, Peters M, Astermark J, Brons PP, Castaman G, et al. Factor VIII gene (F8) mutation and risk of inhibitor development in non-severe hemophilia A. Blood. 2013;122:1954\u201362.","journal-title":"Blood"},{"key":"325_CR14","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1046\/j.1365-2516.2001.00510.x","volume":"7","author":"J Astermark","year":"2001","unstructured":"Astermark J, Berntorp E, White GC, Kroner BL. MIBS Study Group. The Malm\u00f6 International Brother Study (MIBS): further support for genetic predisposition to inhibitor development in hemophilia patients. Haemophilia. 2001;7:267\u201372.","journal-title":"Haemophilia"},{"key":"325_CR15","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1056\/NEJMoa075760","volume":"360","author":"KR Viel","year":"2009","unstructured":"Viel KR, Ameri A, Abshire TC, Iyer RV, Watts RG, Lutcher C, et al. Inhibitors of factor VIII in black patients with hemophilia. N Engl J Med. 2009;360:1618\u201327.","journal-title":"N Engl J Med"},{"key":"325_CR16","first-page":"1","volume":"81","author":"J Blangero","year":"2013","unstructured":"Blangero J, Diego VP, Dyer TD, Almeida M, Peralta J, Kent JW Jr, et al. A kernel of truth: statistical. Adv polygenic Var Compon models complex Hum pedigrees Adv Genet 2013;81:1\u201331.","journal-title":"Adv polygenic Var Compon models complex Hum pedigrees Adv Genet"},{"key":"325_CR17","doi-asserted-by":"publisher","unstructured":"Diego VP, Kent JW Jr, Blangero J. Familial studies: Genetic inferences. In Wright JD (Ed), International Encyclopedia of the Social & Behavioral Sciences. 2015; Vol. 8, 2nd ed., pp. 5259-65. New York, NY: Elsevier. https:\/\/doi.org\/10.1016\/B978-0-08-097086-8.82029-2.","DOI":"10.1016\/B978-0-08-097086-8.82029-2"},{"key":"325_CR18","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1002\/gepi.22114","volume":"42","author":"R Arya","year":"2018","unstructured":"Arya R, Farook VS, Fowler SP, Puppala S, Chittoor G, Resendez RG, et al. Genetic and environmental (physical fitness and sedentary activity) interaction effects on cardiometabolic risk factors in Mexican American children and adolescents. Genet Epidemiol. 2018;42:378\u201393.","journal-title":"Genet Epidemiol"},{"key":"325_CR19","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1177\/1077559519888587","volume":"25","author":"K Pittner","year":"2020","unstructured":"Pittner K, Bakermans-Kranenburg MJ, Alink LRA, Buisman RSM, van den Berg LJM, Block LHCGCC, et al. Estimating the heritability of experiencing child maltreatment in an extended family design. Child Maltreatment. 2020;25:289\u201399.","journal-title":"Child Maltreatment"},{"key":"325_CR20","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.1182\/blood-2005-09-3918","volume":"107","author":"J Astermark","year":"2006","unstructured":"Astermark J, Oldenburg J, Pavlova A, Berntorp E, Lefvert AK. MIBS Study Group. Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A. Blood. 2006;107:3167\u201372.","journal-title":"Blood"},{"key":"325_CR21","doi-asserted-by":"publisher","first-page":"3739","DOI":"10.1182\/blood-2006-05-024711","volume":"108","author":"J Astermark","year":"2006","unstructured":"Astermark J, Oldenburg J, Carlson J, Pavlova A, Kavakli K, Berntorp E, et al. Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A. Blood. 2006;108:3739\u201345.","journal-title":"Blood"},{"key":"325_CR22","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1111\/j.1538-7836.2007.02290.x","volume":"5","author":"J Astermark","year":"2007","unstructured":"Astermark J, Wang X, Oldenburg J, Berntorp E, Lefvert AK. MIBS Study Group. Polymorphisms in the CTLA-4 gene and inhibitor development in patients with severe hemophilia A. J Thrombosis Haemost. 2007;5:263\u20135.","journal-title":"J Thrombosis Haemost"},{"key":"325_CR23","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1111\/j.1538-7836.2009.03636.x","volume":"7","author":"A Pavlova","year":"2009","unstructured":"Pavlova A, Delev D, Lacroix-Desmazes S, Schwaab R, Mende M, Fimmers R, et al. Impact of polymorphisms of the major histocompatibility complex class II, interleukin-10, tumor necrosis factor-alpha and cytotoxic T-lymphocyte antigen-4 genes on inhibitor development in severe hemophilia A. J Thrombosis Haemost. 2009;7:2006\u201315.","journal-title":"J Thrombosis Haemost"},{"key":"325_CR24","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/j.1744-313X.2009.00893.x","volume":"37","author":"D Chaves","year":"2010","unstructured":"Chaves D, Belisario A, Castro G, Santoro M, Rodrigues C. Analysis of cytokine genes polymorphism as markers for inhibitor development in haemophilia A. Int J Immunogenetics. 2010;37:79\u201382.","journal-title":"Int J Immunogenetics"},{"key":"325_CR25","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1111\/j.1365-2516.2010.02473.x","volume":"17","author":"JN Lozier","year":"2011","unstructured":"Lozier JN, Rosenberg PS, Goedert JJ, Menashe I. A case-control study reveals immunoregulatory gene haplotypes that influence inhibitor risk in severe haemophilia A. Haemophilia. 2011;17:641\u20139.","journal-title":"Haemophilia"},{"key":"325_CR26","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1111\/j.1365-2516.2012.02845.x","volume":"18","author":"P Pinto","year":"2012","unstructured":"Pinto P, Ghosh K, Shetty S. Immune regulatory gene polymorphisms as predisposing risk factors for the development of factor VIII inhibitors in Indian severe haemophilia A patients. Haemophilia. 2012;18:794\u20137.","journal-title":"Haemophilia"},{"key":"325_CR27","doi-asserted-by":"publisher","first-page":"e416","DOI":"10.1111\/hae.12015","volume":"18","author":"D Agostini","year":"2012","unstructured":"Agostini D, Rosset C, Botton MR, Kappel DB, Vieira IA, Gorziza RP, et al. Immune system polymorphisms and factor VIII inhibitor formation in Brazilian haemophilia A severe patients. Haemophilia. 2012;18:e416\u2013418.","journal-title":"Haemophilia"},{"key":"325_CR28","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1111\/hae.12168","volume":"19","author":"H Pergantou","year":"2013","unstructured":"Pergantou H, Varela I, Moraloglou O, Economou M, Spanou K, Kapsimali Z, et al. Impact of HLA alleles and cytokine polymorphisms on inhibitors development in children with severe haemophilia A. Haemophilia. 2013;19:706\u201310.","journal-title":"Haemophilia"},{"key":"325_CR29","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.3324\/haematol.2013.084665","volume":"98","author":"Y Repess\u00e9","year":"2013","unstructured":"Repess\u00e9 Y, Peyron I, Dimitrov JD, Dasgupta S, Moshai EF, Costa C, et al. Development of inhibitory antibodies to therapeutic factor VIII in severe hemophilia A is associated with microsatellite polymorphisms in the HMOX1 promoter. Haematologica. 2013;98:1650\u20135.","journal-title":"Haematologica"},{"key":"325_CR30","doi-asserted-by":"publisher","first-page":"3766","DOI":"10.1172\/JCI81859","volume":"125","author":"D Matino","year":"2015","unstructured":"Matino D, Gargaro M, Santagostino E, Di Minno MN, Castaman G, Morfini M, et al. IDO1 suppresses inhibitor development in hemophilia A treated with factor VIII. J Clin Investig. 2015;125:3766\u201381.","journal-title":"J Clin Investig"},{"key":"325_CR31","doi-asserted-by":"publisher","first-page":"620","DOI":"10.3389\/fimmu.2020.00620","volume":"11","author":"D Matino","year":"2020","unstructured":"Matino D, Afraz S, Zhao G, Tieu P, Gargaro M, Fallarino F, et al. Tolerance to FVIII: Role of the immune metabolic enzymes indoleamine 2,3 dyoxigenase-1 and heme oxygenase-1. Front Immunol. 2020;11:620.","journal-title":"Front Immunol"},{"key":"325_CR32","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/ar3204","volume":"13","author":"A Cortes","year":"2011","unstructured":"Cortes A, Brown MA. Promise and pitfalls of the Immunochip. Arthritis Res Ther. 2011;13:101.","journal-title":"Arthritis Res Ther"},{"key":"325_CR33","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1038\/nrg3502","volume":"14","author":"M Parkes","year":"2013","unstructured":"Parkes M, Cortes A, van Heel DA, Brown MA. Genetic insights into common pathways and complex relationships among immune-mediated diseases. Nat Rev Genet. 2013;14:661\u201373.","journal-title":"Nat Rev Genet"},{"key":"325_CR34","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1038\/nm.3270","volume":"19","author":"GS Pandey","year":"2013","unstructured":"Pandey GS, Yanover C, Miller-Jenkins LM, Garfield S, Cole SA, Curran JE, et al. Endogenous factor VIII synthesis from the intron 22-inverted F8 locus may modulate the immunogenicity of replacement therapy for hemophilia A. Nat Med. 2013;19:1318\u201324.","journal-title":"Nat Med"},{"key":"325_CR35","first-page":"612","volume":"34","author":"CK Kasper","year":"1975","unstructured":"Kasper CK, Aledort L, Aronson D, Counts R, Edson JR, van Eys J, et al. Proceedings: a more uniform measurement of factor VIII inhibitors. Thrombosis et Diath Haemorrh. 1975;34:612.","journal-title":"Thrombosis et Diath Haemorrh"},{"key":"325_CR36","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1055\/s-0038-1653759","volume":"73","author":"B Verbruggen","year":"1995","unstructured":"Verbruggen B, Novakova I, Wessels H, Boezeman J, van den Berg M, Mauser-Bunschoten E. The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability. Thrombosis Haemost. 1995;73:247\u201351.","journal-title":"Thrombosis Haemost"},{"key":"325_CR37","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/978-1-62703-339-8_24","volume":"992","author":"E Duncan","year":"2013","unstructured":"Duncan E, Collecutt M, Street A. Nijmegen-Bethesda assay to measure factor VIII inhibitors. Methods Mol Biol. 2013;992:321\u201333.","journal-title":"Methods Mol Biol"},{"key":"325_CR38","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1182\/blood.V99.1.168","volume":"99","author":"RD Bagnall","year":"2002","unstructured":"Bagnall RD, Waseem N, Green PM, Giannelli F. Recurrent inversion breaking intron 1 of the factor VIII gene is a frequent cause of severe hemophilia A. Blood. 2002;99:168\u201374.","journal-title":"Blood"},{"key":"325_CR39","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.ygeno.2005.01.009","volume":"85","author":"J Kelley","year":"2005","unstructured":"Kelley J, de Bono B, Trowsdale J. IRIS: a database surveying known human immune system genes. Genomics. 2005;85:503\u201311.","journal-title":"Genomics"},{"key":"325_CR40","doi-asserted-by":"publisher","first-page":"D1001","DOI":"10.1093\/nar\/gkt1229","volume":"42","author":"D Welter","year":"2014","unstructured":"Welter D, MacArthur J, Morales J, Burdett T, Hall P, Junkins H, et al. The NHGRI GWAS Catalog, a curated resource of SNP-trait associations. Nucleic Acids Res. 2014;42:D1001\u2013D1006.","journal-title":"Nucleic Acids Res"},{"key":"325_CR41","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1086\/519795","volume":"81","author":"S Purcell","year":"2007","unstructured":"Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007;81:559\u201375.","journal-title":"Am J Hum Genet"},{"key":"325_CR42","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1038\/ng1193-236","volume":"5","author":"D Lakich","year":"1993","unstructured":"Lakich D, Kazazian HH Jr, Antonarakis SE, Gitschier J. Inversions disrupting the factor VIII gene are a common cause of severe haemophilia A. Nat Genet. 1993;5:236\u201341.","journal-title":"Nat Genet"},{"key":"325_CR43","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1182\/blood.V86.6.2206.bloodjournal8662206","volume":"86","author":"SE Antonarakis","year":"1995","unstructured":"Antonarakis SE, Rossiter JP, Young M, Horst J, de Moerloose P, Sommer SS, et al. Factor VIII gene inversions in severe hemophilia A: results of an international consortium study. Blood. 1995;86:2206\u201312.","journal-title":"Blood"},{"key":"325_CR44","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1182\/blood-2013-12-530113","volume":"125","author":"ZE Sauna","year":"2015","unstructured":"Sauna ZE, Lozier JN, Kasper CK, Yanover C, Nichols T, Howard TE. The intron-22-inverted F8 locus permits factor VIII synthesis: explanation for low inhibitor risk and a role for pharmacogenomics. Blood. 2015;125:223\u20138.","journal-title":"Blood"},{"key":"325_CR45","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1038\/nbt.2002","volume":"29","author":"C Yanover","year":"2011","unstructured":"Yanover C, Jain N, Pierce G, Howard TE, Sauna ZE. Pharmacogenetics and the immunogenicity of protein therapeutics. Nat Biotechnol. 2011;29:870\u20133.","journal-title":"Nat Biotechnol"},{"key":"325_CR46","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1111\/j.1538-7836.2011.04268.x","volume":"9","author":"K Ogata","year":"2011","unstructured":"Ogata K, Selvaraj SR, Miao HZ, Pipe SW. Most factor VIII B domain missense mutations are unlikely to be causative mutations for severe hemophilia A: implications for genotyping. J Thrombosis Haemost. 2011;9:1183\u201390.","journal-title":"J Thrombosis Haemost"},{"key":"325_CR47","doi-asserted-by":"publisher","first-page":"368","DOI":"10.3109\/03014460.2013.786756","volume":"40","author":"S AL Fadhli","year":"2013","unstructured":"AL Fadhli S, Mohammed EM, Al Shubaili A. Association analysis of nitric oxide synthases: NOS1, NOS2A and NOS3 genes, with multiple sclerosis. Ann Hum Biol. 2013;40:368\u201375.","journal-title":"Ann Hum Biol"},{"key":"325_CR48","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1002\/ana.20092","volume":"55","author":"LF Barcellos","year":"2004","unstructured":"Barcellos LF, Begovich AB, Reynolds RL, Caillier SJ, Brassat D, Schmidt S, et al. Linkage and association with the NOS2A locus on chromosome 17q11 in multiple sclerosis. Ann Neurol. 2004;55:793\u2013800.","journal-title":"Ann Neurol"},{"key":"325_CR49","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.2147\/DMSO.S300525","volume":"14","author":"AMT Gusti","year":"2021","unstructured":"Gusti AMT, Qusti SY, Bahijri SM, Toraih EA, Bokhari S, Attallah SM, et al. Glutathione S-transferase (GSTT1 rs17856199) and nitric oxide synthase (NOS2 rs2297518) genotype combination as potential oxidative stress-related molecular markers for type 2 diabetes mellitus. Diab, Metab Syndr Obes. 2021;14:1385\u2013403.","journal-title":"Diab, Metab Syndr Obes"},{"key":"325_CR50","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1111\/1348-0421.12637","volume":"62","author":"H Liu","year":"2018","unstructured":"Liu H, Wei SP, Zhi LQ, Liu LP, Cao TP, Wang SZ, et al. Synovial GATA1 mediates rheumatoid arthritis progression via transcriptional activation of NOS2 signaling. Microbiol Immunol. 2018;62:594\u2013606.","journal-title":"Microbiol Immunol"},{"key":"325_CR51","doi-asserted-by":"publisher","first-page":"934","DOI":"10.3390\/jpm13060934","volume":"13","author":"CD Ene","year":"2023","unstructured":"Ene CD, Nicolae I. The inflammatory profile orchestrated by inducible nitric oxide synthase in systemic lupus erythematosus. J Personalized Med. 2023;13:934.","journal-title":"J Personalized Med"},{"key":"325_CR52","doi-asserted-by":"publisher","first-page":"3000","DOI":"10.4049\/jimmunol.167.5.3000","volume":"167","author":"FD Shi","year":"2001","unstructured":"Shi FD, Flodstr\u00f6m M, Kim SH, Pakala S, Cleary M, Ljunggren HG, et al. Control of the autoimmune response by type 2 nitric oxide synthase. J Immunol. 2001;167:3000\u20136.","journal-title":"J Immunol"},{"key":"325_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/MIB.0000000000000268","volume":"21","author":"SK Yang","year":"2015","unstructured":"Yang SK, Hong M, Choi H, Zhao W, Jung Y, Haritunians T, et al. Immunochip analysis identification of 6 additional susceptibility loci for Crohn\u2019s disease in Koreans. Inflamm Bowel Dis. 2015;21:1\u20137.","journal-title":"Inflamm Bowel Dis"},{"key":"325_CR54","doi-asserted-by":"publisher","first-page":"e0177080","DOI":"10.1371\/journal.pone.0177080","volume":"12","author":"M Wang","year":"2017","unstructured":"Wang M, Xin L, Cai G, Zhang X, Yang X, Li X, et al. Pathogenic variants screening in seventeen candidate genes on 2p15 for association with ankylosing spondylitis in a Han Chinese population. PLoS One. 2017;12:e0177080.","journal-title":"PLoS One"},{"key":"325_CR55","doi-asserted-by":"publisher","first-page":"64180","DOI":"10.18632\/oncotarget.19419","volume":"8","author":"WC Chen","year":"2017","unstructured":"Chen WC, Wang WC, Okada Y, Chang WP, Chou YH, Chang HH, et al. rs2841277 (PLD4) is associated with susceptibility and rs4672495 is associated with disease activity in rheumatoid arthritis. Oncotarget. 2017;8:64180\u201390.","journal-title":"Oncotarget"},{"key":"325_CR56","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1093\/cvr\/cvaa045","volume":"117","author":"AAV Antikainen","year":"2021","unstructured":"Antikainen AAV, Sandholm N, Tr\u00ebgouet DA, Charmet R, McKnight AJ, Ahluwalia TS, et al. Genome-wide association study on coronary artery disease in type 1 diabetes suggests beta-defensin 127 as a risk locus. Cardiovascular Res. 2021;117:600\u201312.","journal-title":"Cardiovascular Res"},{"key":"325_CR57","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/ng.2231","volume":"44","author":"Y Okada","year":"2012","unstructured":"Okada Y, Terao C, Ikari K, Kochi Y, Ohmura K, Suzuki A, et al. Meta-analysis identifies nine new loci associated with rheumatoid arthritis in the Japanese population. Nat Genet. 2012;44:511\u20136.","journal-title":"Nat Genet"},{"key":"325_CR58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1074\/jbc.RA120.015306","volume":"296","author":"Y Hao","year":"2021","unstructured":"Hao Y, Cr\u00e9quer-Grandhomme A, Javier N, Manzanillo P, Lo M-C, Huang X, et al. Structures and mechanism of human glycosyltransferase \u03b21,3-N-acetylglucosaminyltransferase 2 (B3GNT2), an important player in immune homeostasis. J Biol Chem. 2021;296:1\u201313.","journal-title":"J Biol Chem"},{"key":"325_CR59","first-page":"180","volume":"30","author":"D Ragab","year":"2023","unstructured":"Ragab D, Hammoda RM, El-Gharbawy NH, Salem R. Evaluation of CTLA-4 (+ 49A\/G) polymorphism association with rheumatoid arthritis in Egyptian patients. Egyptian. J Immunol. 2023;30:180\u20139.","journal-title":"J Immunol"},{"key":"325_CR60","doi-asserted-by":"publisher","first-page":"11955","DOI":"10.3390\/ijms231911955","volume":"23","author":"G Vasilev","year":"2022","unstructured":"Vasilev G, Ivanova M, Stanilov I, Miteva L, Stanilova S, Manolova I. Influence of IL10 and TGFB1 promoter polymorphisms on serum cytokine levels in development and severity of RA. Int J Mol Sci. 2022;23:11955.","journal-title":"Int J Mol Sci"},{"key":"325_CR61","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3389\/fimmu.2019.00015","volume":"10","author":"V Salvi","year":"2019","unstructured":"Salvi V, Gianello V, Tiberio L, Sozzani S, Bosisio D. Cytokine targeting by miRNAs in autoimmune diseases. Front Immunol. 2019;10:15.","journal-title":"Front Immunol"},{"key":"325_CR62","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.3390\/diagnostics12112859","volume":"12","author":"IV Rom\u00e1n-Fern\u00e1ndez","year":"2022","unstructured":"Rom\u00e1n-Fern\u00e1ndez IV, Machado-Contreras JR, Mu\u00f1oz-Valle JF, Cruz A, Salazar-Camarena DC, Palafox-S\u00e1nchez CA. Altered PTPN22 and IL10 mRNA expression is associated with disease activity and renal involvement in systemic lupus erythematosus. Diagnostics (Basel). 2022;12:2859.","journal-title":"Diagnostics (Basel)"},{"key":"325_CR63","doi-asserted-by":"publisher","first-page":"311","DOI":"10.4103\/ijd.ijd_82_22","volume":"67","author":"V Kailashiya","year":"2022","unstructured":"Kailashiya V, Singh U, Kailashiya J. CTLA4 gene polymorphism and its association with disease occurrence, clinical manifestations, serum markers and cytokine levels in SLE patients from North India. Indian J Dermatol. 2022;67:311.","journal-title":"Indian J Dermatol"},{"key":"325_CR64","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/imr.12721","volume":"287","author":"N Mitsuiki","year":"2019","unstructured":"Mitsuiki N, Schwab C, Grimbacher B. What did we learn from CTLA-4 insufficiency on the human immune system? Immunological Rev. 2019;287:33\u201349.","journal-title":"Immunological Rev"},{"key":"325_CR65","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.3390\/biomedicines10112825","volume":"10","author":"I Veneziani","year":"2022","unstructured":"Veneziani I, Landolina N, Ricci B, Rossi O, Moretta L, Maggi E. How the immune system responds to allergy immunotherapy. Biomedicines. 2022;10:2825.","journal-title":"Biomedicines"},{"key":"325_CR66","first-page":"829","volume":"81","author":"J Blangero","year":"2009","unstructured":"Blangero J, G\u00f6ring HH, Kent JW, Williams JT, Peterson CP, Almasy L, et al. Quantitative trait nucleotide analysis using Bayesian model selection. 2005 Hum Biol. 2009;81:829\u201347.","journal-title":"2005 Hum Biol"},{"key":"325_CR67","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1182\/bloodadvances.2016002923","volume":"1","author":"JM Johnsen","year":"2017","unstructured":"Johnsen JM, Fletcher SN, Huston H, Roberge S, Martin BK, Kircher M, et al. Novel approach to genetic analysis and results in 3000 hemophilia patients enrolled in the My Life, Our Future initiative. Blood Adv. 2017;1:824\u201334.","journal-title":"Blood Adv"},{"key":"325_CR68","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1111\/hae.13506","volume":"24","author":"BA Konkle","year":"2018","unstructured":"Konkle BA, Johnsen JM, Wheeler M, Watson C, Skinner M, Pierce GF. Genotypes, phenotypes and whole genome sequence: Approaches from the My Life Our Future haemophilia project. Haemophilia. 2018;24:87\u201394.","journal-title":"Haemophilia"},{"key":"325_CR69","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.903838","volume":"9","author":"S Lessard","year":"2022","unstructured":"Lessard S, He C, Rajpal DK, Klinger K, Loh C, Harris T, et al. Genome-wide association study and gene-based analysis of participants with Hemophilia A and inhibitors in the My Life, Our Future Research Repository. Front Med (Lausanne). 2022;9:903838.","journal-title":"Front Med (Lausanne)"},{"key":"325_CR70","doi-asserted-by":"publisher","first-page":"e1003066","DOI":"10.1371\/journal.pcbi.1003066","volume":"9","author":"GS Pandey","year":"2013","unstructured":"Pandey GS, Yanover C, Howard TE, Sauna ZE. Polymorphisms in the F8 gene and MHC-II variants as risk factors for the development of inhibitory anti-factor VIII antibodies during the treatment of hemophilia A: a computational assessment. PLoS Computational Biol. 2013;9:e1003066.","journal-title":"PLoS Computational Biol"},{"key":"325_CR71","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/hae.12004","volume":"19","author":"J Schwarz","year":"2013","unstructured":"Schwarz J, Astermark J, Menius ED, Carrington M, Donfield SM, Gomperts ED, et al. F8 haplotype and inhibitor risk: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort. Haemophilia. 2013;19:113\u20138.","journal-title":"Haemophilia"},{"key":"325_CR72","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1182\/blood-2014-09-599365","volume":"126","author":"D Gunasekera","year":"2015","unstructured":"Gunasekera D, Ettinger RA, Nakaya Fletcher S, James EA, Liu M, Barrett JC, et al. Factor VIII gene variants and inhibitor risk in African American hemophilia A patients. Blood. 2015;126:895\u2013904.","journal-title":"Blood"},{"key":"325_CR73","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.jtha.2022.12.017","volume":"21","author":"AE Ahmed","year":"2023","unstructured":"Ahmed AE, Pratt KP. Race, ethnicity, F8 variants, and inhibitor risk: analysis of the \u201cMy Life Our Future\u201d hemophilia A database. J Thrombosis Haemost. 2023;21:800\u201313.","journal-title":"J Thrombosis Haemost"},{"key":"325_CR74","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1182\/bloodadvances.2018030452","volume":"3","author":"W Jankowski","year":"2019","unstructured":"Jankowski W, Park Y, McGill J, Maraskovsky E, Hofmann M, Diego VP, et al. Peptides identified on monocyte-derived dendritic cells: a marker for clinical immunogenicity to FVIII products. Blood Adv. 2019;3:1429\u201340.","journal-title":"Blood Adv"},{"key":"325_CR75","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1111\/jth.14647","volume":"18","author":"VP Diego","year":"2020","unstructured":"Diego VP, Luu BW, Hofmann M, Dinh LV, Almeida M, Powell JS, et al. Quantitative HLA-class-II\/factor VIII (FVIII) peptidomic variation in dendritic cells correlates with the immunogenic potential of therapeutic FVIII proteins in hemophilia A. J Thrombosis Haemost. 2020;18:201\u201316.","journal-title":"J Thrombosis Haemost"},{"key":"325_CR76","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1111\/j.1365-2516.2005.01121.x","volume":"11","author":"G Jayandharan","year":"2005","unstructured":"Jayandharan G, Shaji RV, Baidya S, Nair SC, Chandy M, Srivastava A. Identification of factor VIII gene mutations in 101 patients with haemophilia A: mutation analysis by inversion screening and multiplex PCR and CSGE and molecular modelling of 10 novel missense substitutions. Haemophilia. 2005;11:481\u201391.","journal-title":"Haemophilia"},{"key":"325_CR77","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1111\/j.1365-2516.2008.01687.x","volume":"14","author":"GC Ma","year":"2008","unstructured":"Ma GC, Chang SP, Chen M, Kuo SJ, Chang CS, Shen MC. The spectrum of the factor 8 (F8) defects in Taiwanese patients with haemophilia A. Haemophilia. 2008;14:787\u201395.","journal-title":"Haemophilia"},{"key":"325_CR78","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1182\/blood-2005-04-1371","volume":"107","author":"J Goudemand","year":"2006","unstructured":"Goudemand J, Rothschild C, Demiguel V, Vinciguerrat C, Lambert T, Chambost H, et al. Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A. Blood. 2006;107:46\u201351.","journal-title":"Blood"},{"key":"325_CR79","first-page":"239a","volume":"84","author":"JE Addiego Jr","year":"1994","unstructured":"Addiego JE Jr, Kasper C, Abildgaard C, Lusher J, Hilgartner M, Glader B, et al. Increased frequency of inhibitors in African American hemophilia A patients. Blood. 1994;84:239a\u2013239a.","journal-title":"Blood"},{"key":"325_CR80","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1046\/j.1365-2516.1998.0146c.x","volume":"4","author":"LM Aledort","year":"1998","unstructured":"Aledort LM, Dimichele DM. Inhibitors occur more frequently in African-American and Latino haemophiliacs. Haemophilia. 1998;4:68\u201368.","journal-title":"Haemophilia"},{"key":"325_CR81","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s10038-020-00845-2","volume":"66","author":"Y Momozawa","year":"2021","unstructured":"Momozawa Y, Mizukami K. Unique roles of rare variants in the genetics of complex diseases in humans. J Hum Genet. 2021;66:11\u201323.","journal-title":"J Hum Genet"}],"updated-by":[{"DOI":"10.1038\/s41435-025-00345-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000}}],"container-title":["Genes & Immunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41435-025-00325-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41435-025-00325-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41435-025-00325-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T07:04:11Z","timestamp":1758870251000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41435-025-00325-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,22]]},"references-count":81,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["325"],"URL":"https:\/\/doi.org\/10.1038\/s41435-025-00325-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3371095\/v1","asserted-by":"object"}]},"ISSN":["1476-5470"],"issn-type":[{"value":"1476-5470","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,22]]},"assertion":[{"value":"19 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: In this article the author\u2019s name R. Rajalingam was incorrectly written as R. Raja.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2025","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41435-025-00345-3","URL":"https:\/\/doi.org\/10.1038\/s41435-025-00345-3","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"There are NO relevant conflicts for any co-author. BWL, LVD, JSP, and TEH are respectively the Director of Technical Operations, Director of Drug Discovery, Chief Medical Officer and Chief Scientific Officer of Haplogenics Corporation. Dr. Henry Mead was an employee of BioMarin and is currently a consultant for Haplogenics Corporation. Dr. Paul Lehmann is the Co-Founder, President and CEO of Cellular Technology Limited.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All methods used in the PATH study were performed in accordance with the relevant guidelines and regulations. All human subjects research components of the PATH study were approved by the IRB Committees at the Los Angeles Veterans Affairs Medical Center (IRB: 2009-091280) and Bloodworks Northwest (IRB: 13018). All participants in the PATH study gave informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"IRB \/ ethics committee approval and consent to participate"}}]}}